Antiproliferative Effect of Metformin on the Endometrium - a Clinical Trial

  • Tabrizi, Ali Dastranj (Women's Reproductive Health Research Center, Medicine, Tabriz University of Medical Sciences) ;
  • Melli, Manijeh Sayyah (Women's Reproductive Health Research Center, Medicine, Tabriz University of Medical Sciences) ;
  • Foroughi, Meraj (Women's Reproductive Health Research Center, Medicine, Tabriz University of Medical Sciences) ;
  • Ghojazadeh, Morteza (Women's Reproductive Health Research Center, Medicine, Tabriz University of Medical Sciences) ;
  • Bidadi, Sanam (Women's Reproductive Health Research Center, Medicine, Tabriz University of Medical Sciences)
  • Published : 2015.01.06


Background: Unopposed estrogen has a central role in development of endometrial benign, premalignant and malignant lesions. The aim of this study was to evaluate the anti-estrogenic effect of metformin on endometrial histology in comparison with progesterone. Materials and Methods: A total of 43 patients who were referred to our center for abnormal uterine bleeding and had a histologic diagnosis were disordered proliferative endometrium or simple endometrial hyperplasia were included and randomly distributed in two groups treated with metformin (500mg Bid) or megestrol (40mg daily), respectively, for three months. After this period the patients were evaluated by another endometrial biopsy to assess the impact of the two drugs in restoring normal endometrial histology. Results: Our findings revealed that metformin could induce endometrial atrophy in 21 out of 22 patients (95.5%) while this positive response was achieved in only 13 out of 21 patients (61.9%) in the megstrol group. In addition two low grade endometrial carcinomas in the metformin group responded very well. Conclusions: We conclude that metformin could be used as an effective antiestrogenic agent in control of abnormal endometrial proliferative disorders.


Endometrial hyperplasia;metformin;mestrol;anti-estrogenic influence;endometrial atrophy


  1. Chao A, Lin CY, Tsai CL, et al (2013). Estrogen stimulates the proliferation of human endometrial cancer cells by stabilizing nucleophosmin/B23 (NPM/B23). J Mol Med (Berl), 91, 249-59.
  2. Campagnoli C, Abba C, Ambroggio Set al (2013). Life-style and metformin for the prevention of endometrial pathology in postmenopausal women. Gynecol Endocrinol, 29, 119-24.
  3. Eftekhar Z, Izadi-Mood N, Yarandi F, et al (2009). Efficacy of megestrol acetate (Megace) in the treatment of patients with early endometrial adenocarcinoma: our experiences with 21 patients. Int J Gynecol Cancer, 19, 249-52.
  4. Acmaz G, Aksoy H, Albayrak E, et al (2014). Evaluation of endometrial precancerous lesions in postmenopausal obese women-a high risk group? Asian Pac J Cancer Prev, 15, 195-8.
  5. Avci CB, Harman E, Dodurga Y, Susluer SY, Gunduz C (2013). Therapeutic potential of an anti-diabetic drug, metformin: alteration of miRNA expression in prostate cancer cells. Asian Pac J Cancer Prev, 14, 765-8.
  6. Fryer LG, Parbu-Patel A, Carling D (2002). The anti-diabetic drugs rosiglitazone and metformin stimulate AMP-activated protein kinase through distinct signaling pathways. J Biol Chem, 277, 25226-32.
  7. Huang X, Wellschleger S, Shapiro N, et al (2008). Important role of the LKB1-AMPK pathway in suppressing tumorigenesis in PTEN-deficient mice. Biochem J, 412, 211-21.
  8. Hardie DG (2003). The AMP-activated protein kinase cascade: the key sensor of cellular energy status. Endocrinology, 144, 5179-83.
  9. Jarboe EA, Mutter GL (2010). Endometrial intraepithelial neoplasia. Semin Diagn Pathol, 27, 215-25.
  10. Ko EM, Walter P, Jackson A, et al (2014). Metformin is associated with improved survival in endometrial cancer. Gynecol Oncol, 132, 438-42
  11. Libby G, Donnelly LA, Donnan PT, et al (2009). New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes. Diabetes Care, 32, 1620-5
  12. Mutter GL, Zaino RJ, Baak JP, et al (2007). Benign endometrial hyperplasia sequence and endometrial intraepithelial neoplasia. Int J Gynecol Pathol, 26, 103-14.
  13. Mutter GL (2000). Endometrial intraepithelial neoplasia (EIN): Will it bring order to chaos? Gynecol Oncol,76, 287-290.
  14. Mutter GL, Baak JPA, Crum CP, et al (2002). Endometrial precancer diagnosis by histopathology, clonal analysis, and computerized morphometry. J Pathol, 190, 462-9.
  15. Nevadunsky NS, Van Arsdale A, Strickler HD, et al (2013). Metformin use and endometrial non endometriod cancer survival. Gynecol Oncol, 132, 236-40
  16. Navaratnarajah R, Pillay OC, Hardiman P (2008). Polycystic ovary syndrome and endometrial cancer. Semin Reprod Med, 26, 62-71.
  17. Prat J, Bentley RC, Russel P, Anderson MC (2009). Endometrial intraepithelial neoplasia. In 'Robboy's Pathology of Female Reproductive Tract', Eds. Elsevier, China, pp 367-397.
  18. Perino A, Quartararo P, Catinella E, et al (1987). Treatment of endometrial hyperplasia with levonorgestrel releasing intrauterine devices. Acta Eur Fertil, 18, 137-40.
  19. Randall TC, Kurman RJ (1997). Progestin treatment of atypical hyperplasia and well-differentiated carcinoma of the endometrium in women under age 40. Obstet Gynecol, 90, 434-40
  20. Sarfstein R, Friedman Y, Attias-Geva Z, et al (2013). Metformin down regulates the insulin/IGF-I signaling pathway and inhibits different uterine serous carcinoma (USC) cells proliferation and migration in p53-dependent or -independent manners. PLoS One, 19, 61537.
  21. Shen ZQ, Zhu HT, Lin JF. (2008). Reverse of progestin-resistant atypical endometrial hyperplasia by metformin and oral contraceptives. Obstet Gynecol, 112, 465-7.
  22. Shafiee MN, Khan G, Ariffin R, et al (2013). Preventing endometrial cancer risk in polycystic ovarian syndrome (PCOS) women: Could metformin help? Gynecol Oncol, 13, 1277-8
  23. Thigpen JT, Brady MF, Alvarez RD, et al (1999). Oral medroxyprogesterone acetate in the treatment of advanced or recurrent endometrial carcinoma: a dose-response study by the Gynecologic Oncology Group. J Clin Oncol, 17, 1736-44.
  24. Tas M, Kutuk MS, Serin IS, et al (2013). Comparison of antiproliferative effects of metformine and progesterone on estrogen-induced endometrial hyperplasia in rats. Gynecol Endocrinol, 29, 311-4.
  25. van Meurs HS, Bleeker MC, van der Velden J, et al (2013). The incidence of endometrial hyperplasia and cancer in 1031 patients with a granulosa cell tumor of the ovary: long-term follow-up in a population-based cohort study. Int J Gynecol Cancer, 23, 1417-22.
  26. Wheeler DT, Bristow RE, Kurman RJ (2007). Histologic alterations in endometrial hyperplasia and well-differentiated carcinoma treated with progestins. Am J Surg Pathol, 31, 988-98.
  27. Zhou G, Myers R, Li Y, et al (2001). Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest, 108, 1167-74
  28. Zakikhani M, Dowling R, Fantus IG, et al (2006). Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. Cancer Res, 66, 10267-73.

Cited by

  1. The Impact of Diabetes on Gynecologic Cancer: Current Status and Future Directions vol.4, pp.4, 2015,
  2. The expanding role of metformin in cancer: an update on antitumor mechanisms and clinical development vol.11, pp.4, 2016,
  3. A comparison between the effects of metformin and megestrol on simple endometrial hyperplasia vol.33, pp.2, 2017,
  4. Progestin Intrauterine Devices and Metformin: Endometrial Hyperplasia and Early Stage Endometrial Cancer Medical Management vol.5, pp.3, 2017,
  5. Panobinostat Enhances Growth Suppressive Effects of Progestin on Endometrial Carcinoma by Increasing Progesterone Receptor and Mitogen-Inducible Gene-6 vol.8, pp.4, 2017,
  6. Induction of apoptosis by metformin and progesterone in estrogen-induced endometrial hyperplasia in rats: involvement of the bcl-2 family proteins pp.1473-0766, 2017,
  7. Proliferation and metastatic potential of endometrial cancer cells in response to metformin treatment in a high versus normal glucose environment vol.12, pp.5, 2016,
  8. Metformin as a Therapeutic Target in Endometrial Cancers vol.8, pp.2234-943X, 2018,